Making the Most of the Clinical Toolbox: Improving Outcomes in HABP and VABP
Back to course
Video Transcription
Video Summary
Asset Subtitle
Infection, Quality and Patient Safety, 2020
Asset Caption

The Society of Critical Care Medicine's Critical Care Congress features internationally renowned faculty and content sessions highlighting the most up-to-date, evidence-based developments in critical care medicine. This is a presentation from the 2020 Critical Care Congress held February 16-19, 2020, in Orlando, Florida, USA.

This program is supported by an educational grant from Merck & Co., Inc.

Learning Objectives

  • Explain the evolving epidemiology and etiology of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
  • Discuss key safety and efficacy data for newer agents being used for the treatment of HABP and VABP
  • Develop tailored treatment strategies for HABP and/or VABP that support the principles of antibiotic stewardship
  • Coordinate with members of the multiprofessional care team to improve timely diagnoses

Welcome and Introductions

Marin H. Kollef

HABP and VABP: Epidemiology, Microbiology, and Clinical Consequences

Richard Wunderink

Considerations for Antiobiotic Therapy for MDR Infections in HABP and VABP

Debra Goff

New and Emerging Therapies: A Closer Look at the Data

Richard Wunderink

Individualizing Therapy to Support Antimicrobial Stewardship and Improved Outcomes

Marin Kollef

Concluding Remarks and Audience Q&A

Marin Kollef

 

 

Meta Tag
Content Type Presentation
Knowledge Area Quality and Patient Safety
Knowledge Area Infection
Knowledge Level Foundational
Knowledge Level Intermediate
Knowledge Level Advanced
Membership Level Select
Membership Level Professional
Membership Level Associate
Tag Guidelines
Tag Mortality
Year 2020
Keywords
appropriate antibiotic therapy
nosocomial pneumonia
rapid diagnostic tests
new antibiotics
ceftolizumab plus tezobactam
ceftazidime/avibactam
personalized antibiotic dosing
gram-negative pathogens
individualized therapy
responsible antibiotic use
improve outcomes